GeneIII
Latest round
- Series A
Last raised
- Jul 2025
Total raised
- $3.5M
Investors
- 2
About GeneIII
Based in Nanjing, China, and established in 2021, GeneIII engages in the development and commercialization of synthetic biology applications in the health and wellness sectors. Wang, a biomedical postdoctoral researcher from the University of Illinois Urbana-Champaign, and is composed of a highly educated workforce, with 60% holding postgraduate degrees. GeneIII operates two main product lines: skincare bioactive raw materials and products, and dietary supplement ingredients and products. Its skincare range includes skin serum, wrinkle-reducing serum, hydrolyzed sodium hyaluronate, and ergothioneine, while its dietary supplements feature ergothioneine oral capsules, amaranth probiotic drinks, probiotics, and cold-pack gels targeting rhinitis. The company generates revenue through the sale of its skincare and dietary supplement products, both directly and via business partnerships.
Who invested in GeneIII
2 investors across 1 round
See all investors in GeneIII
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jul 16, 2025
Amount
$3.5M
Investors
Questions about GeneIII
Who invested in GeneIII?
GeneIII has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has GeneIII raised?
GeneIII has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did GeneIII last raise money?
GeneIII's most recent round on record is a Series A, in Jul 2025.
What does GeneIII do?
Based in Nanjing, China, and established in 2021, GeneIII engages in the development and commercialization of synthetic biology applications in the health and wellness sectors.
Where is GeneIII headquartered?
GeneIII is headquartered in Nanjing, China.
Which VCs invest in companies like GeneIII?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at GeneIII's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like GeneIII? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.